Financhill
Sell
21

VYGR Quote, Financials, Valuation and Earnings

Last price:
$3.20
Seasonality move :
-10.01%
Day range:
$3.13 - $3.43
52-week range:
$2.65 - $9.55
Dividend yield:
0%
P/E ratio:
6.11x
P/S ratio:
2.77x
P/B ratio:
0.65x
Volume:
656.3K
Avg. volume:
786K
1-year change:
-57.84%
Market cap:
$177.1M
Revenue:
$80M
EPS (TTM):
-$1.46

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
VYGR
Voyager Therapeutics
$9.5M -$0.52 -67.89% -190.56% $16.00
ATNM
Actinium Pharmaceuticals
-- -$0.35 -100% -7.24% $5.00
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
NNVC
Nanoviricides
-- -$0.20 -- -26.67% --
OGEN
Oragenics
-- -- -- -- $1.00
TOVX
Theriva Biologics
-- -$0.47 -- -95.63% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
VYGR
Voyager Therapeutics
$3.20 $16.00 $177.1M 6.11x $0.00 0% 2.77x
ATNM
Actinium Pharmaceuticals
$1.43 $5.00 $44.6M -- $0.00 0% --
NBY
NovaBay Pharmaceuticals
$0.63 $0.85 $3.6M -- $0.00 0% 0.16x
NNVC
Nanoviricides
$1.39 -- $22.3M -- $0.00 0% --
OGEN
Oragenics
$1.44 $1.00 $1M -- $0.00 0% 0.46x
TOVX
Theriva Biologics
$0.45 $7.00 $3.7M -- $0.00 0% 0.33x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
VYGR
Voyager Therapeutics
-- 0.610 -- 5.92x
ATNM
Actinium Pharmaceuticals
-- -3.037 -- 9.03x
NBY
NovaBay Pharmaceuticals
4.54% -0.044 1.51% 0.75x
NNVC
Nanoviricides
-- -0.318 -- --
OGEN
Oragenics
-- 0.068 -- --
TOVX
Theriva Biologics
-- -3.388 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
VYGR
Voyager Therapeutics
-- -$34.7M -26.82% -26.82% -535.97% -$38.6M
ATNM
Actinium Pharmaceuticals
-- -$16.6M -95.08% -95.08% -12769.14% -$7.6M
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
NNVC
Nanoviricides
-- -$2.2M -- -- -- -$2M
OGEN
Oragenics
-- -$2M -- -- -- -$2.1M
TOVX
Theriva Biologics
-- -$4.4M -- -- -- -$4.8M

Voyager Therapeutics vs. Competitors

  • Which has Higher Returns VYGR or ATNM?

    Actinium Pharmaceuticals has a net margin of -479.24% compared to Voyager Therapeutics's net margin of -11511.11%. Voyager Therapeutics's return on equity of -26.82% beat Actinium Pharmaceuticals's return on equity of -95.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    VYGR
    Voyager Therapeutics
    -- -$0.53 $272.7M
    ATNM
    Actinium Pharmaceuticals
    -- -$0.51 $36.4M
  • What do Analysts Say About VYGR or ATNM?

    Voyager Therapeutics has a consensus price target of $16.00, signalling upside risk potential of 393.06%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 249.65%. Given that Voyager Therapeutics has higher upside potential than Actinium Pharmaceuticals, analysts believe Voyager Therapeutics is more attractive than Actinium Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    VYGR
    Voyager Therapeutics
    11 0 0
    ATNM
    Actinium Pharmaceuticals
    2 1 0
  • Is VYGR or ATNM More Risky?

    Voyager Therapeutics has a beta of 0.849, which suggesting that the stock is 15.088% less volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.325, suggesting its less volatile than the S&P 500 by 132.486%.

  • Which is a Better Dividend Stock VYGR or ATNM?

    Voyager Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Voyager Therapeutics pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VYGR or ATNM?

    Voyager Therapeutics quarterly revenues are $6.5M, which are larger than Actinium Pharmaceuticals quarterly revenues of $81K. Voyager Therapeutics's net income of -$31M is lower than Actinium Pharmaceuticals's net income of -$15.9M. Notably, Voyager Therapeutics's price-to-earnings ratio is 6.11x while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Voyager Therapeutics is 2.77x versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VYGR
    Voyager Therapeutics
    2.77x 6.11x $6.5M -$31M
    ATNM
    Actinium Pharmaceuticals
    -- -- $81K -$15.9M
  • Which has Higher Returns VYGR or NBY?

    NovaBay Pharmaceuticals has a net margin of -479.24% compared to Voyager Therapeutics's net margin of -49.65%. Voyager Therapeutics's return on equity of -26.82% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    VYGR
    Voyager Therapeutics
    -- -$0.53 $272.7M
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About VYGR or NBY?

    Voyager Therapeutics has a consensus price target of $16.00, signalling upside risk potential of 393.06%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 35.98%. Given that Voyager Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Voyager Therapeutics is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    VYGR
    Voyager Therapeutics
    11 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is VYGR or NBY More Risky?

    Voyager Therapeutics has a beta of 0.849, which suggesting that the stock is 15.088% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

  • Which is a Better Dividend Stock VYGR or NBY?

    Voyager Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Voyager Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VYGR or NBY?

    Voyager Therapeutics quarterly revenues are $6.5M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Voyager Therapeutics's net income of -$31M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Voyager Therapeutics's price-to-earnings ratio is 6.11x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Voyager Therapeutics is 2.77x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VYGR
    Voyager Therapeutics
    2.77x 6.11x $6.5M -$31M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns VYGR or NNVC?

    Nanoviricides has a net margin of -479.24% compared to Voyager Therapeutics's net margin of --. Voyager Therapeutics's return on equity of -26.82% beat Nanoviricides's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    VYGR
    Voyager Therapeutics
    -- -$0.53 $272.7M
    NNVC
    Nanoviricides
    -- -$0.14 --
  • What do Analysts Say About VYGR or NNVC?

    Voyager Therapeutics has a consensus price target of $16.00, signalling upside risk potential of 393.06%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 367.63%. Given that Voyager Therapeutics has higher upside potential than Nanoviricides, analysts believe Voyager Therapeutics is more attractive than Nanoviricides.

    Company Buy Ratings Hold Ratings Sell Ratings
    VYGR
    Voyager Therapeutics
    11 0 0
    NNVC
    Nanoviricides
    0 0 0
  • Is VYGR or NNVC More Risky?

    Voyager Therapeutics has a beta of 0.849, which suggesting that the stock is 15.088% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.802%.

  • Which is a Better Dividend Stock VYGR or NNVC?

    Voyager Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Voyager Therapeutics pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VYGR or NNVC?

    Voyager Therapeutics quarterly revenues are $6.5M, which are larger than Nanoviricides quarterly revenues of --. Voyager Therapeutics's net income of -$31M is lower than Nanoviricides's net income of -$2.2M. Notably, Voyager Therapeutics's price-to-earnings ratio is 6.11x while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Voyager Therapeutics is 2.77x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VYGR
    Voyager Therapeutics
    2.77x 6.11x $6.5M -$31M
    NNVC
    Nanoviricides
    -- -- -- -$2.2M
  • Which has Higher Returns VYGR or OGEN?

    Oragenics has a net margin of -479.24% compared to Voyager Therapeutics's net margin of --. Voyager Therapeutics's return on equity of -26.82% beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    VYGR
    Voyager Therapeutics
    -- -$0.53 $272.7M
    OGEN
    Oragenics
    -- -$3.60 --
  • What do Analysts Say About VYGR or OGEN?

    Voyager Therapeutics has a consensus price target of $16.00, signalling upside risk potential of 393.06%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 1983.54%. Given that Oragenics has higher upside potential than Voyager Therapeutics, analysts believe Oragenics is more attractive than Voyager Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    VYGR
    Voyager Therapeutics
    11 0 0
    OGEN
    Oragenics
    0 1 0
  • Is VYGR or OGEN More Risky?

    Voyager Therapeutics has a beta of 0.849, which suggesting that the stock is 15.088% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

  • Which is a Better Dividend Stock VYGR or OGEN?

    Voyager Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Voyager Therapeutics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VYGR or OGEN?

    Voyager Therapeutics quarterly revenues are $6.5M, which are larger than Oragenics quarterly revenues of --. Voyager Therapeutics's net income of -$31M is lower than Oragenics's net income of -$2.2M. Notably, Voyager Therapeutics's price-to-earnings ratio is 6.11x while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Voyager Therapeutics is 2.77x versus 0.46x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VYGR
    Voyager Therapeutics
    2.77x 6.11x $6.5M -$31M
    OGEN
    Oragenics
    0.46x -- -- -$2.2M
  • Which has Higher Returns VYGR or TOVX?

    Theriva Biologics has a net margin of -479.24% compared to Voyager Therapeutics's net margin of --. Voyager Therapeutics's return on equity of -26.82% beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    VYGR
    Voyager Therapeutics
    -- -$0.53 $272.7M
    TOVX
    Theriva Biologics
    -- -$1.55 --
  • What do Analysts Say About VYGR or TOVX?

    Voyager Therapeutics has a consensus price target of $16.00, signalling upside risk potential of 393.06%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1455.56%. Given that Theriva Biologics has higher upside potential than Voyager Therapeutics, analysts believe Theriva Biologics is more attractive than Voyager Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    VYGR
    Voyager Therapeutics
    11 0 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is VYGR or TOVX More Risky?

    Voyager Therapeutics has a beta of 0.849, which suggesting that the stock is 15.088% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

  • Which is a Better Dividend Stock VYGR or TOVX?

    Voyager Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Voyager Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VYGR or TOVX?

    Voyager Therapeutics quarterly revenues are $6.5M, which are larger than Theriva Biologics quarterly revenues of --. Voyager Therapeutics's net income of -$31M is lower than Theriva Biologics's net income of -$4.3M. Notably, Voyager Therapeutics's price-to-earnings ratio is 6.11x while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Voyager Therapeutics is 2.77x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VYGR
    Voyager Therapeutics
    2.77x 6.11x $6.5M -$31M
    TOVX
    Theriva Biologics
    0.33x -- -- -$4.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Hershey Stock Be In 1 Year?
Where Will Hershey Stock Be In 1 Year?

Chocolate stocks used to be the epitome of sleepy stability,…

Where Will KNOT Stock Be In 1 Year?
Where Will KNOT Stock Be In 1 Year?

In the case of KNOT Offshore Partners (KNOP), most headlines…

Why Is Goldman Sachs Stock Up So Much?
Why Is Goldman Sachs Stock Up So Much?

Investment banking giant Goldman Sachs (NYSE:GS) has sharply outperformed the…

Stock Ideas

Buy
63
Is NVDA Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 53x

Buy
60
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 42x

Sell
48
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Sell
18
CNC alert for Jul 3

Centene [CNC] is down 0.36% over the past day.

Sell
12
MOH alert for Jul 3

Molina Healthcare [MOH] is up 0.74% over the past day.

Buy
67
GBX alert for Jul 3

Greenbrier Companies [GBX] is down 0.51% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock